When all actions on the part of the clinician seem to have failed, the rheumatologist should ask themselves several questions:
- Is the diagnosis correct?
- Is the disease still active, and am I treating inflammation or damage?
- Is the patient compliant with treatment?
- Are fibromyalgia, depression, sleep disturbance or different issues at play?
- Have I set realistic expectations for the patient in terms of anticipated results?
By running through this list of questions, the clinician can step back and gain a better understanding of the whole picture of the patient, thereby enabling holistic, more effective care of the patient as a person.
In Sum
The session provided by Dr. Deodhar was rich with insight, and the audience was left with many clinical pearls to help in the management of axSpA and non-radiographic axSpA.
Jason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.
References
- Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777–783.
- Bohn R, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol. 2018 Mar–Apr;36(2):263–274.
- Weber U, Lambert RG, Østergaard M, et al. The diagnostic utility of magnetic resonance imaging in spondyloarthritis: An international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010 Oct;62(10):3048–3058.
- Deodhar A, Gill T, Magrey M. Human leukocyte antigen b27-negative axial spondyloarthritis: What do we know? ACR Open Rheumatol. 2023 Jul;5(7):333–344.
- Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.
- Hamilton L, Barkham N, Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxford). 2017 Feb;56(2):313–316.